[Skip to Content]

Upstate Active Clinical Trials

Study Title:

NRG-LU005 - LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB

What is the purpose of the study?

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Upstate Institutional Review Board (IRB) Number:

1458566

Study/Protocol ID:

NRG-LU005

Study Phase:

II/III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

ClinicalTrials.Gov ID:

NCT03811002

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Nicole D Bunyea
Phone: 315-464-8276
Email: bunyean@upstate.edu

Return to Previous Page || Search Again

Top